Drug Patents owned by Kastle Theraps Llc

1. Drug name - KYNAMRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7015315 KASTLE THERAPS LLC Gapped oligonucleotides
Mar, 2023

(5 months from now)

US7101993 KASTLE THERAPS LLC Oligonucleotides containing 2′-O-modified purines
Sep, 2023

(10 months from now)

US7511131 KASTLE THERAPS LLC Antisense modulation of apolipoprotein B expression
Jan, 2027

(4 years from now)

IN201107578P4 KASTLE THERAPS LLC Antisense Modulation Of Apolipoprotein B Expression
Nov, 2023

(1 year, 1 month from now)

IN219847B KASTLE THERAPS LLC An Antisense Compound And A Composition Thereof
Nov, 2023

(1 year, 1 month from now)

IN200501218P4 KASTLE THERAPS LLC An Antisense Compound And A Composition Thereof
Nov, 2023

(1 year, 1 month from now)

IN299478B KASTLE THERAPS LLC Antisense Modulation Of Apolipoprotein B Expression
Nov, 2023

(1 year, 1 month from now)

EP604409B1 KASTLE THERAPS LLC Oligonucleotide Analogs For Detecting And Modulating Rna Activity And Gene Expression
Jan, 2011

(11 years ago)

EP604409A4 KASTLE THERAPS LLC Compositions And Methods For Detecting And Modulating Rna Activity And Gene Expression.
Jan, 2011

(11 years ago)

EP604409A1 KASTLE THERAPS LLC Oligonucleotide Analogs For Detecting And Modulating Rna Activity And Gene Expression
Jan, 2011

(11 years ago)

EP517859A1 KASTLE THERAPS LLC Oligonucleotide Therapies For Modulating The Effects Of Herpesviruses
Feb, 2011

(11 years ago)

EP517859A4 KASTLE THERAPS LLC Oligonucleotide Therapies For Modulating The Effects Of Herpesviruses
Feb, 2011

(11 years ago)

EP517859B1 KASTLE THERAPS LLC Oligonucleotide Therapies For Modulating The Effects Of Herpesviruses
Feb, 2011

(11 years ago)

EP529008A4 KASTLE THERAPS LLC Modulation Of Gene Expression Through Interference With Rna Secondary Structure
Apr, 2011

(11 years ago)

EP529008A1 KASTLE THERAPS LLC Modulation Of Gene Expression Through Interference With Rna Secondary Structure
Apr, 2011

(11 years ago)

EP529008B1 KASTLE THERAPS LLC Modulation Of Gene Expression Through Interference With Rna Secondary Structure
Apr, 2011

(11 years ago)

EP544757A4 KASTLE THERAPS LLC Novel Polyamine Conjugated Oligonucleotides
Jun, 2011

(11 years ago)

EP544757A1 KASTLE THERAPS LLC Novel Polyamine Conjugated Oligonucleotides
Jun, 2011

(11 years ago)

EP544757B1 KASTLE THERAPS LLC Novel Polyamine Conjugated Oligonucleotides
Jun, 2011

(11 years ago)

EP544716A4 KASTLE THERAPS LLC Oligonucleotide Modulation Of Cell Adhesion
Jul, 2011

(11 years ago)

EP544716A1 KASTLE THERAPS LLC Oligonucleotide Modulation Of Cell Adhesion
Jul, 2011

(11 years ago)

EP544716B1 KASTLE THERAPS LLC Oligonucleotide Modulation Of Cell Adhesion
Jul, 2011

(11 years ago)

EP544792A1 KASTLE THERAPS LLC Novel Nucleoside Analogs
Aug, 2011

(11 years ago)

EP544792B1 KASTLE THERAPS LLC Novel Nucleoside Analogs
Aug, 2011

(11 years ago)

EP549615B1 KASTLE THERAPS LLC Sugar Modified Oligonucleotides That Detect And Modulate Gene Expression
Aug, 2011

(11 years ago)

EP549615A1 KASTLE THERAPS LLC Sugar Modified Oligonucleotides That Detect And Modulate Gene Expression
Aug, 2011

(11 years ago)

EP544792A4 KASTLE THERAPS LLC Novel Nucleoside Analogs
Aug, 2011

(11 years ago)

EP549615A4 KASTLE THERAPS LLC Sugar Modified Oligonucleotides That Detect And Modulate Gene Expression
Aug, 2011

(11 years ago)

EP544713A4 KASTLE THERAPS LLC Oligonucleotides For Modulating The Effects Of Cytomegalovirus Infections
Aug, 2011

(11 years ago)

EP544713A1 KASTLE THERAPS LLC Oligonucleotides For Modulating The Effects Of Cytomegalovirus Infections
Aug, 2011

(11 years ago)

EP544713B1 KASTLE THERAPS LLC Oligonucleotides For Modulating The Effects Of Cytomegalovirus Infections
Aug, 2011

(11 years ago)

EP586520A1 KASTLE THERAPS LLC Backbone Modified Oligonucleotide Analogs
May, 2012

(10 years ago)

EP586520A4 KASTLE THERAPS LLC Backbone Modified Oligonucleotide Analogs
May, 2012

(10 years ago)

EP586520B1 KASTLE THERAPS LLC Backbone Modified Oligonucleotide Analogs
May, 2012

(10 years ago)

EP586570B1 KASTLE THERAPS LLC Backbone Modified Oligonucleotide Analogues
May, 2012

(10 years ago)

EP586570A1 KASTLE THERAPS LLC Backbone Modified Oligonucleotide Analogues
May, 2012

(10 years ago)

EP586570A4 KASTLE THERAPS LLC Backbone Modified Oligonucleotide Analogues
May, 2012

(10 years ago)

EP590082A1 KASTLE THERAPS LLC Antisense Oligonucleotide Inhibition Of The Ras Gene
Jun, 2012

(10 years ago)

EP590082A4 KASTLE THERAPS LLC Antisense Oligonucleotide Inhibition Of The Ras Gene.
Jun, 2012

(10 years ago)

EP590082B1 KASTLE THERAPS LLC Antisense Oligonucleotide Inhibition Of The Ras Gene
Jun, 2012

(10 years ago)

EP655088A1 KASTLE THERAPS LLC Oligonucleotides Having Chiral Phosphorus Linkages
Oct, 2012

(9 years ago)

EP655088A4 KASTLE THERAPS LLC Oligonucleotides Having Chiral Phosphorus Linkages.
Oct, 2012

(9 years ago)

EP655088B1 KASTLE THERAPS LLC Oligonucleotides Having Chiral Phosphorus Linkages
Oct, 2012

(9 years ago)

EP724447A4 KASTLE THERAPS LLC Derivatized Oligonucleotides Having Improved Uptake And Other Properties
Oct, 2012

(9 years ago)

EP724447B1 KASTLE THERAPS LLC Derivatized Oligonucleotides Having Improved Uptake
Oct, 2012

(9 years ago)

EP724447A1 KASTLE THERAPS LLC Derivatized Oligonucleotides Having Improved Uptake
Oct, 2012

(9 years ago)

EP618925A1 KASTLE THERAPS LLC Antisense Oligonucleotides
Dec, 2012

(9 years ago)

EP1044987B1 KASTLE THERAPS LLC Gapped 2'-Modified Oligonucleotides
Dec, 2012

(9 years ago)

EP1044987A3 KASTLE THERAPS LLC Gapped 2'-Modified Oligonucleotides
Dec, 2012

(9 years ago)

EP1044987A2 KASTLE THERAPS LLC Gapped 2'-Modified Oligonucleotides
Dec, 2012

(9 years ago)

EP1695979A2 KASTLE THERAPS LLC Gapped Modified Oligonucleotides
Dec, 2012

(9 years ago)

EP1695979B1 KASTLE THERAPS LLC Gapped Modified Oligonucleotides
Dec, 2012

(9 years ago)

EP1695979A3 KASTLE THERAPS LLC Gapped 2' Modified Oligonucleotides
Dec, 2012

(9 years ago)

EP618925A4 KASTLE THERAPS LLC Gapped 2' Modified Oligonucleotides.
Dec, 2012

(9 years ago)

EP618925B2 KASTLE THERAPS LLC Antisense Oligonucleotides
Dec, 2012

(9 years ago)

EP618925B1 KASTLE THERAPS LLC Antisense Oligonucleotides
Dec, 2012

(9 years ago)

EP672180B1 KASTLE THERAPS LLC Oligonucleotide Modulation Of Protein Kinase C
Feb, 2013

(9 years ago)

EP672180A4 KASTLE THERAPS LLC Oligonucleotide Modulation Of Protein Kinase C.
Feb, 2013

(9 years ago)

EP672180A1 KASTLE THERAPS LLC Oligonucleotide Modulation Of Protein Kinase C
Feb, 2013

(9 years ago)

EP649429B1 KASTLE THERAPS LLC Heteroatomic Oligonucleoside Linkages
May, 2013

(9 years ago)

EP649429A1 KASTLE THERAPS LLC Heteroatomic Oligonucleoside Linkages
May, 2013

(9 years ago)

EP649429A4 KASTLE THERAPS LLC Heteroatomic Oligonucleoside Linkages.
May, 2013

(9 years ago)

EP651759B1 KASTLE THERAPS LLC Novel 2'-O-Alkyl Nucleosides And Phosphoramidites Processes For The Preparation And Uses Thereof
Jul, 2013

(9 years ago)

EP1223173B1 KASTLE THERAPS LLC Novel 2'-O-Alkyl Nucleosides And Phosphoramidites Processes For The Preparation And Uses Thereof
Jul, 2013

(9 years ago)

EP1223173A2 KASTLE THERAPS LLC Novel 2'-O-Alkyl Nucleosides And Phosphoramidites Processes For The Preparation And Uses Thereof
Jul, 2013

(9 years ago)

EP1223173A3 KASTLE THERAPS LLC Novel 2'-O-Alkyl Nucleosides And Phosphoramidites Processes For The Preparation And Uses Thereof
Jul, 2013

(9 years ago)

EP651759A1 KASTLE THERAPS LLC Novel 2'-O-Alkyl Nucleosides And Phosphoramidites Processes For The Preparation And Uses Thereof
Jul, 2013

(9 years ago)

EP651759A4 KASTLE THERAPS LLC Novel 2'-O-Alkyl Nucleosides And Phosphoramidites Processes For The Preparation And Uses Thereof.
Jul, 2013

(9 years ago)

EP662003A1 KASTLE THERAPS LLC Oligonucleotide Modulation Of Cell Adhesion
Aug, 2013

(9 years ago)

EP662003A4 KASTLE THERAPS LLC Oligonucleotide Modulation Of Cell Adhesion.
Aug, 2013

(9 years ago)

EP662003B1 KASTLE THERAPS LLC Oligonucleotide Modulation Of Cell Adhesion
Aug, 2013

(9 years ago)

EP672193B1 KASTLE THERAPS LLC Use Of Oligonucleotides Having A Conserved G 4 Core Sequence For The Preparation Of A Medicament
Sep, 2013

(9 years ago)

EP672193A4 KASTLE THERAPS LLC Oligonucleotides Having A Conserved G 4? Core Sequence.
Sep, 2013

(9 years ago)

EP672193A1 KASTLE THERAPS LLC Use Of Oligonucleotides Having A Conserved G 4 Core Sequence For The Preparation Of A Medicament
Sep, 2013

(9 years ago)

EP716604A4 KASTLE THERAPS LLC Thiol-Derivatized Nucleosides And Oligonucleosides
Aug, 2014

(8 years ago)

EP716604B1 KASTLE THERAPS LLC Thiol-Derivatized Nucleosides And Oligonucleosides
Aug, 2014

(8 years ago)

EP716604A1 KASTLE THERAPS LLC Thiol-Derivatized Nucleosides And Oligonucleosides
Aug, 2014

(8 years ago)

EP728139A4 KASTLE THERAPS LLC Gapped Oligonucleotides
Sep, 2014

(8 years ago)

EP728139A1 KASTLE THERAPS LLC Amine-Derivatized Nucleosides And Oligonucleosides
Sep, 2014

(8 years ago)

EP728139B1 KASTLE THERAPS LLC Amine-Derivatized Nucleosides And Oligonucleosides
Sep, 2014

(8 years ago)

EP734391A1 KASTLE THERAPS LLC Pna-Dna-Pna Chimeric Macromolecules
Nov, 2014

(7 years ago)

EP734391A4 KASTLE THERAPS LLC Pna-Dna-Pna Chimeric Macromolecules
Nov, 2014

(7 years ago)

EP734391B1 KASTLE THERAPS LLC Pna-Dna-Pna Chimeric Macromolecules
Nov, 2014

(7 years ago)

EP731807A1 KASTLE THERAPS LLC N-2 Substituted Purines
Nov, 2014

(7 years ago)

EP731807B1 KASTLE THERAPS LLC N-2 Substituted Purines
Nov, 2014

(7 years ago)

EP731807A4 KASTLE THERAPS LLC N-2 Substituted Purines
Nov, 2014

(7 years ago)

EP881914B1 KASTLE THERAPS LLC Methoxyethoxy Oligonucleotides For Modulation Of Protein Kinase C Expression
Feb, 2017

(5 years ago)

EP881914A1 KASTLE THERAPS LLC Methoxyethoxy Oligonucleotides For Modulation Of Protein Kinase C Expression
Feb, 2017

(5 years ago)

EP881914A4 KASTLE THERAPS LLC Gapped Oligonucleotides
Feb, 2017

(5 years ago)

EP1218395A4 KASTLE THERAPS LLC Antisense Modulation Of X-Linked Inhibitor Of Apoptosis Expression
Jan, 2020

(2 years ago)

EP1218395A1 KASTLE THERAPS LLC Antisense Modulation Of X-Linked Inhibitor Of Apoptosis Expression
Jan, 2020

(2 years ago)

EP1218395B1 KASTLE THERAPS LLC Antisense Modulation Of X-Linked Inhibitor Of Apoptosis Expression
Jan, 2020

(2 years ago)

EP1325019A4 KASTLE THERAPS LLC Antisense Modulation Of Clusterin Expression
Sep, 2021

(1 year, 24 days ago)

EP1325019A1 KASTLE THERAPS LLC Antisense Modulation Of Clusterin Expression
Sep, 2021

(1 year, 24 days ago)

EP1325019B1 KASTLE THERAPS LLC Antisense Modulation Of Clusterin Expression
Sep, 2021

(1 year, 24 days ago)

EP2174945A1 KASTLE THERAPS LLC Antisense Modulation Of Apolipoprotein B Expression
Jul, 2022

(2 months ago)

EP2174945B1 KASTLE THERAPS LLC Antisense Modulation Of Apolipoprotein B Expression
Jul, 2022

(2 months ago)

EP2336318A1 KASTLE THERAPS LLC Antisense Modulation Of Apolipoprotein B Expression
Nov, 2023

(1 year, 1 month from now)

EP1569695A4 KASTLE THERAPS LLC Antisense Modulation Of Apolipoprotein B Expression
Nov, 2023

(1 year, 1 month from now)

EP1569695A2 KASTLE THERAPS LLC Antisense Modulation Of Apolipoprotein B Expression
Nov, 2023

(1 year, 1 month from now)

EP1569695B1 KASTLE THERAPS LLC Antisense Modulation Of Apolipoprotein B Expression
Nov, 2023

(1 year, 1 month from now)

EP2336318B1 KASTLE THERAPS LLC Antisense Modulation Of Apolipoprotein B Expression
Nov, 2023

(1 year, 1 month from now)

Drugs and Companies using MIPOMERSEN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
200MG/ML (200MG/ML) SOLUTION;SUBCUTANEOUS Discontinued

availability in other generic markets.

Click on the highlighted region to filter.